News

iZafe Group's CEO, Anders Segerström, presented the company at the Aktiespararna’s event Stora Aktiedagarna on November 29. The presentation was held in Swedish and includes updates on the acquisition of Pilloxa, the significance of winning...

iZafe Group (publ.) hereby announces that CEO Anders Segerström will present an investor presentation on Wednesday, November 29th at 4:25 PM at the "Stora Aktiedagarna" in Stockholm. On Wednesday, November 29th at 4:25 PM, iZafe will present...

iZafe Group AB ("iZafe Group") announces that the agreement with the Västra Götaland Region (VGR) for the delivery of Dosell medication dispensers has now been concluded. This follows the earlier communication of the award decision...

iZafe Group AB (publ.) today presents its report for the third quarter on November 17. Financial Highlights Summary Key Events During the Quarter Key Events After the End of the Quarter CEO's CommentWe look back on a quarter where our business plan...

iZafe Group AB (publ.) is pleased to announce that the company's major shareholders have appointed a nomination committee in consultation with the chairman of the board, Björn Rosengren. This step marks a significant milestone in enhancing corporate...

iZafe Group AB ("iZafe Group") announces that, in partnership with Atea Sverige AB, they have been awarded a contract with Västra Götalandsregionen for the provision of iZafe's medication dispensers, Dosell. The contract covers...

iZafe Group AB ("iZafe Group") is pleased to announce the successful implementation of their medication robot, Dosell, in Spain. The company has now completed all necessary technical integrations and adjustments required to launch Dosell in...

iZafe Group's CEO, Anders Segerström, has today acquired an additional 208,333 B-shares in the company. The transaction was completed at a total value of 50,000 SEK, equivalent to 0.24 SEK per share. With this latest purchase, Anders Segerström...

The MAR stamp was mistakenly not included in the initial PM. iZafe Group AB (publ.) presents today, August 25, its report for the second quarter. Financial Performance in Summary Significant events during the quarter Significant events after the end of...

iZafe Group AB (publ.) presents today, August 25, its report for the second quarter. Financial Performance in Summary Significant events during the quarter Significant events after the end of the quarter Comments from CEOI am pleased to share with you...

iZafe group AB (publ.) is proud to present an exciting new development in the company's identity and expression. With the goal of further strengthening its presence on the international scene, the company is today launching an updated logo and design...

iZafe Group AB ("iZafe Group") announces today that they are now removing exclusive sales of Dosell via Apoteket.se and are instead opening up to future sales via several sales channels. This after receiving great international impact for their...

iZafe Group AB ("iZafe Group") is pleased to announce that it has signed a collaboration agreement with Ti-Medi for the rights to sell and market the medication robot Dosell. Ti-Medi's minimum commitment over a four-year period is worth...

iZafe Group AB ("iZafe Group") hereby announces that the company has signed a cooperation agreement with MDM Pulse for the right to sell and market the pharmaceutical robot Dosell in Portugal. MDM Pulse's minimum commitment over a five-year...

iZafe Group AB ("iZafe Group" or the “Company”) hereby announces that that the Spanish company Ti-Medi has acquired approximately five percent of the shares in the Company, which makes Ti-Medi one of iZafe Group's largest shareholders...

As part of the internationalization strategy, iZafe Group has entered into a collaboration with the fintech platform eucaps.com. This is to facilitate the dissemination of information and dialogue with existing shareholders and to be able to reach out...

iZafe Group AB (”iZafe Group” or the ”Company”) today announces the outcome of the exercise of warrants of series TO13B, which were issued in the fourth quarter of 2022. In total, 96,805,841 warrants of series TO13B were exercised...

iZafe Group (publ.) hereby announces that its wholly owned subsidiary Pilloxa AB is expanding its digital support for patients to Germany in collaboration with Chiesi´s local office. The implementation of the service will have an initial allowance...